StreetInsider.com News Articles

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Shah Preetam

Fri, 17 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260717/26784474.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Shah Preetam

Fri, 17 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260717/26784474.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: DeMuth Peter

Fri, 17 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260717/26784476.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: DeMuth Peter

Fri, 17 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260717/26784476.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Haqq Christopher

Fri, 17 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260717/26784481.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Haqq Christopher

Fri, 17 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260717/26784481.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Connelly Robert

Fri, 17 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260717/26784472.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Connelly Robert

Fri, 17 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260717/26784472.html

Form SCHEDULE 13G Elicio Therapeutics, Filed by: Moti Investments LLC

Thu, 16 Jul 2026 11:42:00 -0400

si-local-file:///var/storage/secattach/20260716/26778368.html

Form SCHEDULE 13G Elicio Therapeutics, Filed by: Moti Investments LLC

Thu, 16 Jul 2026 11:42:00 -0400

si-local-file:///var/storage/secattach/20260716/26778368.html

Form SCHEDULE 13G/A Elicio Therapeutics, Filed by: Knoll Capital Management, LLC

Wed, 08 Jul 2026 14:18:00 -0400

si-local-file:///var/storage/secattach/20260708/26747051.html

Form SCHEDULE 13G/A Elicio Therapeutics, Filed by: Knoll Capital Management, LLC

Wed, 08 Jul 2026 14:18:00 -0400

si-local-file:///var/storage/secattach/20260708/26747051.html

Elicio Therapeutics closes $15M registered direct offering

Mon, 06 Jul 2026 16:05:14 -0400

Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced the closing of a registered direct offering, raising approximately $15 million in gross proceeds before placement agent fees and other expenses.

The offering involved the sale of 4,380,313 shares of common stock, with participation from two new institutional investors and one existing shareholder, according to a press release from the Boston-based clinical-stage biotechnology company.

Elicio said it intends to use the net proceeds primarily to fund the planned Phase 1 clinical development of its lead candidate, ELI-002 7P, in metastatic pancreatic ductal adenocarcinoma (PDAC), as well as to advance its broader pipeline and platform. Remaining funds

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

Mon, 06 Jul 2026 16:05:00 -0400

BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the closing of its previously announced registered direct offering (the “Offering”) pursuant to a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock. The gross proceeds to the Company were approximately $15 million, before deducting placement agents’ fees and other Offering expenses. Elicio intends to use the

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

Mon, 06 Jul 2026 16:05:00 -0400

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

Mon, 06 Jul 2026 16:05:00 -0400

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

Mon, 06 Jul 2026 16:05:00 -0400

Form 424B5 Elicio Therapeutics,

Thu, 02 Jul 2026 08:17:00 -0400

si-local-file:///var/storage/secattach/20260702/26724301.html

Form 424B5 Elicio Therapeutics,

Thu, 02 Jul 2026 08:17:00 -0400

si-local-file:///var/storage/secattach/20260702/26724301.html

Form 8-K Elicio Therapeutics, For: Jul 01

Thu, 02 Jul 2026 06:20:00 -0400

si-local-file:///var/storage/secattach/20260702/26723723.html

Form 8-K Elicio Therapeutics, For: Jul 01

Thu, 02 Jul 2026 06:20:00 -0400

si-local-file:///var/storage/secattach/20260702/26723723.html

Elicio Therapeutics prices $15M registered direct offering

Thu, 02 Jul 2026 00:25:23 -0400

Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced the pricing of a registered direct offering of 4,380,313 shares of common stock at an aggregate gross proceeds of approximately $15 million, before placement agent fees and other offering expenses.

The offering is led by two new institutional investors, with participation from an existing shareholder. Closing is expected on or about July 6, 2026, subject to customary closing conditions.

The company said it intends to use net proceeds primarily to fund the planned Phase 1 clinical development of its lead candidate, ELI-002 7P, in metastatic pancreatic ductal adenocarcinoma (PDAC), as well as its broader pipeline and

Elicio Therapeutics prices $15M registered direct offering

Thu, 02 Jul 2026 00:25:23 -0400

The offering is led by two new institutional investors, with participation from an existing shareholder. Closing is expected on or about July 6, 2026, subject to customary closing conditions.

Elicio Therapeutics prices $15M registered direct offering

Thu, 02 Jul 2026 00:25:23 -0400

The offering is led by two new institutional investors, with participation from an existing shareholder. Closing is expected on or about July 6, 2026, subject to customary closing conditions.

Elicio Therapeutics prices $15M registered direct offering

Thu, 02 Jul 2026 00:25:23 -0400

The offering is led by two new institutional investors, with participation from an existing shareholder. Closing is expected on or about July 6, 2026, subject to customary closing conditions.